Regeneron Pharmaceuticals Expects Preliminary (Unaudited) Q4 2023 U.S. Net Product Sales Of EyleaHD (Aflibercept) Injection 8mg Of Approximately $123M, With Sales Eylea (Aflibercept) Injection Of Approximately $1.34B - 8K
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals reported preliminary Q4 2023 U.S. net product sales for EyleaHD (Aflibercept) Injection 8mg at approximately $123M, and for Eylea (Aflibercept) Injection at approximately $1.34B, according to an 8K filing.
January 08, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals expects strong Q4 2023 sales for its products EyleaHD and Eylea, with sales reaching $123M and $1.34B respectively in the U.S.
The reported preliminary sales figures for EyleaHD and Eylea are likely to be viewed positively by investors, as they indicate robust revenue generation from key products. This could lead to increased investor confidence and a potential short-term uptick in REGN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100